Mesa Laboratories Declares Quarterly Dividend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy MLAB?
Source: Newsfilter
- Quarterly Dividend Announcement: Mesa Laboratories' Board of Directors has declared a quarterly dividend of $0.16 per share of common stock, payable on June 15, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Shareholder Record Date: The record date for this dividend is set for May 29, 2026, ensuring that shareholders holding shares before this date will receive the dividend, thereby promoting long-term investment intentions among shareholders.
- Industry Leadership: Mesa Laboratories is a global leader in life science tools and quality control solutions, focusing on the pharmaceutical, healthcare, and medical device industries, dedicated to enhancing product integrity and safety, which drives the company's sustained growth.
- Forward-Looking Statements: The company’s forward-looking statements indicate that future performance may be affected by various risks and uncertainties, cautioning investors to be aware of potential market changes and industry dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLAB
Wall Street analysts forecast MLAB stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 99.340
Low
83.00
Averages
99.00
High
115.00
Current: 99.340
Low
83.00
Averages
99.00
High
115.00
About MLAB
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Citigroup, Maximus, Lindsay Declare Quarterly Dividends
- Citigroup Dividend: Citigroup's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on May 22, 2026, to shareholders of record as of May 4, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Maximus Dividend Approval: Maximus announced a quarterly cash dividend of $0.33 per share, set to be paid on June 1, 2026, with a record date of May 15, 2026, reflecting the company's stable profitability in the government services sector.
- Lindsay Dividend Declaration: Lindsay declared a quarterly cash dividend of $0.37 per share, payable on May 29, 2026, to shareholders of record as of May 15, 2026, indicating continued growth in the irrigation and infrastructure equipment market.
- MV Oil Trust Distribution: MV Oil Trust announced a distribution of net profits for the quarter ending March 31, 2026, with unitholders receiving $0.170 per unit, totaling $1,955,000, showcasing the trust's profitability and stable cash flow.
See More
Mesa Laboratories Declares Quarterly Dividend of $0.16
- Quarterly Dividend Announcement: Mesa Laboratories declares a quarterly dividend of $0.16 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 0.7% reflects the company's robust performance in the current market environment, potentially attracting income-seeking investors looking for reliable returns.
- Financial Performance Beats Expectations: Mesa Laboratories reports a GAAP EPS of $0.65, exceeding expectations by $0.37, with revenue of $65.13 million surpassing estimates by $1.9 million, showcasing the company's strong growth potential in the medical device sector.
- Management Change: The appointment of a new CEO may bring a fresh strategic direction and management style, further enhancing the company's innovation and competitive edge in the healthcare industry.
See More
Mesa Laboratories Declares Quarterly Dividend
- Quarterly Dividend Announcement: Mesa Laboratories' Board of Directors has declared a quarterly dividend of $0.16 per share of common stock, payable on June 15, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Shareholder Record Date: The record date for this dividend is set for May 29, 2026, ensuring that shareholders holding shares before this date will receive the dividend, thereby promoting long-term investment intentions among shareholders.
- Industry Leadership: Mesa Laboratories is a global leader in life science tools and quality control solutions, focusing on the pharmaceutical, healthcare, and medical device industries, dedicated to enhancing product integrity and safety, which drives the company's sustained growth.
- Forward-Looking Statements: The company’s forward-looking statements indicate that future performance may be affected by various risks and uncertainties, cautioning investors to be aware of potential market changes and industry dynamics.
See More
MLAB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: MLAB's 52-week low is $55.45 per share, while the high is $131.20, with the last trade at $82.00, indicating significant volatility in its stock price over the past year, reflecting varying market expectations about its future performance.
- Market Trend Observation: The current stock price of $82.00 is above the 52-week low, suggesting a partial recovery of investor confidence; however, it remains significantly below the high, which may indicate a cautious market sentiment regarding its growth potential.
- Technical Indicator Reference: MLAB's stock price has crossed above the 200-day moving average, potentially attracting more technical analysis investors, which could further drive the stock price upward and enhance market activity.
- Investor Sentiment Assessment: Although the current stock price is positioned in the middle of the 52-week range, market views on MLAB remain divided, necessitating close monitoring of upcoming earnings reports and market dynamics for informed decision-making.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Mesa Laboratories CEO Transition and Earnings Beat Expectations
- Executive Transition: Mesa Laboratories' president and CEO Gary Owens will step down on April 12, 2026, with Siddhartha Kadia appointed as his successor effective April 13, 2026, indicating a strategic leadership shift to align with future growth objectives.
- New CEO Background: Prior to this role, Siddhartha Kadia served as CEO of Calibre Scientific, and his extensive industry experience is expected to bring fresh perspectives and leadership to Mesa Laboratories, potentially driving further innovation in the medical device sector.
- Earnings Highlights: Mesa Laboratories reported a GAAP EPS of $0.65, beating expectations by $0.37, while revenue reached $65.13 million, exceeding forecasts by $1.9 million, showcasing the company's strong market performance and profitability.
- Market Reaction: The earnings beat is likely to boost investor confidence in Mesa Laboratories, potentially driving its stock price higher and providing a solid foundation for the incoming CEO's tenure.
See More
Citigroup, Maximus, Lindsay Declare Quarterly Dividends
- Citigroup Dividend: Citigroup's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on May 22, 2026, to shareholders of record as of May 4, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Maximus Dividend Approval: Maximus announced a quarterly cash dividend of $0.33 per share, set to be paid on June 1, 2026, with a record date of May 15, 2026, reflecting the company's stable profitability in the government services sector.
- Lindsay Dividend Declaration: Lindsay declared a quarterly cash dividend of $0.37 per share, payable on May 29, 2026, to shareholders of record as of May 15, 2026, indicating continued growth in the irrigation and infrastructure equipment market.
- MV Oil Trust Distribution: MV Oil Trust announced a distribution of net profits for the quarter ending March 31, 2026, with unitholders receiving $0.170 per unit, totaling $1,955,000, showcasing the trust's profitability and stable cash flow.
See More
Mesa Laboratories Declares Quarterly Dividend of $0.16
- Quarterly Dividend Announcement: Mesa Laboratories declares a quarterly dividend of $0.16 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 0.7% reflects the company's robust performance in the current market environment, potentially attracting income-seeking investors looking for reliable returns.
- Financial Performance Beats Expectations: Mesa Laboratories reports a GAAP EPS of $0.65, exceeding expectations by $0.37, with revenue of $65.13 million surpassing estimates by $1.9 million, showcasing the company's strong growth potential in the medical device sector.
- Management Change: The appointment of a new CEO may bring a fresh strategic direction and management style, further enhancing the company's innovation and competitive edge in the healthcare industry.
See More
Mesa Laboratories Declares Quarterly Dividend
- Quarterly Dividend Announcement: Mesa Laboratories' Board of Directors has declared a quarterly dividend of $0.16 per share of common stock, payable on June 15, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Shareholder Record Date: The record date for this dividend is set for May 29, 2026, ensuring that shareholders holding shares before this date will receive the dividend, thereby promoting long-term investment intentions among shareholders.
- Industry Leadership: Mesa Laboratories is a global leader in life science tools and quality control solutions, focusing on the pharmaceutical, healthcare, and medical device industries, dedicated to enhancing product integrity and safety, which drives the company's sustained growth.
- Forward-Looking Statements: The company’s forward-looking statements indicate that future performance may be affected by various risks and uncertainties, cautioning investors to be aware of potential market changes and industry dynamics.
See More
MLAB Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: MLAB's 52-week low is $55.45 per share, while the high is $131.20, with the last trade at $82.00, indicating significant volatility in its stock price over the past year, reflecting varying market expectations about its future performance.
- Market Trend Observation: The current stock price of $82.00 is above the 52-week low, suggesting a partial recovery of investor confidence; however, it remains significantly below the high, which may indicate a cautious market sentiment regarding its growth potential.
- Technical Indicator Reference: MLAB's stock price has crossed above the 200-day moving average, potentially attracting more technical analysis investors, which could further drive the stock price upward and enhance market activity.
- Investor Sentiment Assessment: Although the current stock price is positioned in the middle of the 52-week range, market views on MLAB remain divided, necessitating close monitoring of upcoming earnings reports and market dynamics for informed decision-making.
See More
U.S. Stocks Mixed in Morning Trading
- Dow Jones Decline: On Tuesday, the Dow Jones fell approximately 0.07% to 47,709.07 points after market opening, reflecting cautious sentiment towards economic data that may impact investor confidence.
- NASDAQ Gains: In contrast, the NASDAQ rose by 0.13% to 22,724.49 points, indicating a relatively strong performance in tech stocks, which could attract more capital inflows into this sector.
- United Natural Foods' Mixed Results: Shares of United Natural Foods, Inc. (NYSE:UNFI) dropped around 7% on Tuesday, as its quarterly earnings of 62 cents per share exceeded the analyst consensus of 51 cents, yet its sales of $7.947 billion fell short of the $8.108 billion estimate, highlighting market challenges.
- Commodity Market Fluctuations: Oil prices fell by 8% to $87.24, while gold increased by 2.3% to $5,221.20, reflecting heightened demand for safe-haven assets, which may also impact the profitability of related companies.
See More
Mesa Laboratories CEO Transition and Earnings Beat Expectations
- Executive Transition: Mesa Laboratories' president and CEO Gary Owens will step down on April 12, 2026, with Siddhartha Kadia appointed as his successor effective April 13, 2026, indicating a strategic leadership shift to align with future growth objectives.
- New CEO Background: Prior to this role, Siddhartha Kadia served as CEO of Calibre Scientific, and his extensive industry experience is expected to bring fresh perspectives and leadership to Mesa Laboratories, potentially driving further innovation in the medical device sector.
- Earnings Highlights: Mesa Laboratories reported a GAAP EPS of $0.65, beating expectations by $0.37, while revenue reached $65.13 million, exceeding forecasts by $1.9 million, showcasing the company's strong market performance and profitability.
- Market Reaction: The earnings beat is likely to boost investor confidence in Mesa Laboratories, potentially driving its stock price higher and providing a solid foundation for the incoming CEO's tenure.
See More
